10. Navigating Targeted Therapies & PRRT • Dr. Jennifer Chan • 2026 NCF Conference
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jennifer Chan, medical oncologist at Dana-Farber Cancer Institute, presents “Navigating Targeted Therapies and PRRT.” Dr. Chan explains how peptide receptor radionuclide therapy, or PRRT, and molecularly targeted therapies are used to treat advanced neuroendocrine tumors. She discusses how PRRT targets somatostatin receptor-positive tumors, how Lutetium-177 dotatate works, when PRRT may be considered, and what patients should know about treatment schedule, radiation safety precautions, benefits, and possible side effects. This presentation also covers targeted therapy options for neuroendocrine tumors, including everolimus, cabozantinib, sunitinib, and belzutifan for patients with VHL disease. Dr. Chan explains how these treatments work, what side effects patients may experience, and why treatment decisions should be individualized based on tumor type, somatostatin receptor status, disease burden, symptoms, medical history, quality of life, and multidisciplinary input. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jennifer Chan, medical oncologist at Dana-Farber Cancer Institute, presents “Navigating Targeted Therapies and PRRT.” Dr. Chan explains how peptide receptor radionuclide therapy, or PRRT, and molecularly targeted therapies are used to treat advanced neuroendocrine tumors. She discusses how PRRT targets somatostatin receptor-positive tumors, how Lutetium-177 dotatate works, when PRRT may be considered, and what patients should know about treatment schedule, radiation safety precautions, benefits, and possible side effects. This presentation also covers targeted therapy options for neuroendocrine tumors, including everolimus, cabozantinib, sunitinib, and belzutifan for patients with VHL disease. Dr. Chan explains how these treatments work, what side effects patients may experience, and why treatment decisions should be individualized based on tumor type, somatostatin receptor status, disease burden, symptoms, medical history, quality of life, and multidisciplinary input. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.